Based on the promising phase II data demonstrating the efficacy of BV for the treatment of CD30+ CTCL [10,11], the ALCANZA phase III trial reported on the efficacy of single-agent BV compared to physician’s choice bexarotene or methotrexate in 131 patients with previously treated CTCL–mycosis fungoides (MF) and primary cutaneous anaplastic large-cell lymphoma (C-ALCL). Here, TNFRSF8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.